Chemical subgroup
L01EM – Phosphatidylinositol-3-kinase (Pi3K)-Inhibitoren
7Decisions
20Patient groups
Added benefit by patient group
- Considerable1
- Non-quantifiable2
- Not proven15
- Lesser benefit2
Decisions, newest first
- 2026-02-19ItovebiInavolisibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2022-07-21CopiktraDuvelisibNot proven
- 2022-07-21CopiktraDuvelisibNot proven: 4 of 4 patient groups
- 2021-02-18PiqrayAlpelisibNot proven: 3 of 5 patient groupsLesser benefit: 2 of 5 patient groups
- 2017-03-16ZydeligIdelalisibNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2016-09-15ZydeligIdelalisibNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2015-03-19ZydeligIdelalisibNot proven
Data status: 2026-10-29